Head-to-head trials answer a question that placebo comparisons cannot: how does an experimental medicine perform against a treatment clinicians already use? On October 28, 2026, Eli Lilly released topline findings from TRANSCEND-T2D-2, a Phase 3 trial comparing investigational retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes. Lilly reported greater average reductions in A1C and body weight with both tested retatrutide doses after 80 weeks. That is meaningful comparative evidence, but it is not a general verdict about every drug, dose or patient.
Retatrutide Won the Reported Weight and A1C Comparisons
Lilly reported A1C reductions of 2.2 percentage points with both retatrutide 9 mg and 12 mg, versus 1.8 percentage points with Ozempic 2 mg. Average weight reduction was 19.5% and 20.9% for retatrutide, compared with 9.4% for Ozempic. The corresponding average weight reductions were approximately 44.3, 47.4 and 20.9 pounds, respectively.
| Treatment | A1C change | Body-weight change |
|---|---|---|
| Retatrutide 9 mg | −2.2 percentage points | −19.5% |
| Retatrutide 12 mg | −2.2 percentage points | −20.9% |
| Ozempic 2 mg | −1.8 percentage points | −9.4% |
The numbers come from the company’s efficacy estimand, which estimates outcomes if randomized participants had remained on study treatment through 80 weeks, allowing specified dose modifications and without extended use of additional blood-sugar medication. It should not be read as the expected result for everyone who starts a prescription outside a trial.
A Meaningful Head-to-Head Test, With a Specific Design
The randomized, open-label trial enrolled 1,298 adults whose type 2 diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. Participants were assigned in a 2:2:1 ratio to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg. Retatrutide treatment began at 2 mg and was gradually escalated toward the assigned target dose.
The trial’s primary objective was to demonstrate that retatrutide 12 mg was noninferior to Ozempic 2 mg in A1C reduction after 80 weeks. Lilly reported that primary and key secondary endpoints were met. A1C superiority for the 9 mg dose was nominally significant rather than controlled for family-wise error in the same way as the 12 mg comparison. This statistical nuance matters when interpreting the results.
Because patients and investigators knew which therapy was being administered, subjective outcomes and behavior could have been influenced by treatment assignment. A1C is a laboratory measurement and less dependent on patient perception, but the open-label design remains part of the evidence.
Why Three Receptor Pathways Matter
Retatrutide activates GIP, GLP-1 and glucagon receptors, while semaglutide activates the GLP-1 receptor. The triple-agonist approach is designed to affect overlapping pathways involved in appetite, glucose regulation and metabolic energy balance. That mechanism gives scientists a reason to test retatrutide, but more receptor targets do not automatically make a drug better.
The clinically important question is whether a mechanistic difference produces outcomes that justify treatment burden and risk. TRANSCEND-T2D-2 supplies an important active-comparator result for A1C and weight loss. It does not establish superiority in preventing cardiovascular events, kidney disease or other long-term complications.
Safety Is Part of the Result, Not an Afterthought
Lilly reported treatment discontinuation due to adverse events in 4.8% of the retatrutide 9 mg group, 7.9% of the 12 mg group and 2.7% of the Ozempic group. Gastrointestinal side effects were prominent: diarrhea occurred in 28.3%, 32.7% and 26.4%, respectively, while nausea occurred in 21.2%, 23.8% and 21.3%.
The company also reported dysesthesia—altered skin sensation—in 4.8% and 6.5% of the two retatrutide groups versus 2.7% with Ozempic. Most reported adverse events were mild to moderate, according to Lilly. Those findings do not erase the efficacy results, but they underline why the average weight-loss figure is not the only outcome relevant to future patients and prescribers.
Winning a head-to-head comparison answers the question the trial asked. It does not answer every question patients and clinicians still have.
The Ozempic Comparator Matters
Ozempic 2 mg is a meaningful comparator because it is an approved treatment dose for type 2 diabetes. But this study did not compare retatrutide with every obesity-specific semaglutide regimen or with tirzepatide. Lilly says a separate retatrutide-versus-tirzepatide Phase 3 trial, TRIUMPH-5, is ongoing.
It would therefore be incorrect to turn these findings into a definitive ranking of all obesity medicines. Comparing headline percentages across unrelated trials is particularly unreliable when study populations, treatment durations, estimands and approaches to missing data differ.
Topline Data Are a Milestone, Not the Final Clinical Verdict
As of the October 28 announcement, the detailed TRANSCEND-T2D-2 results had not yet been presented at a medical meeting or published in a peer-reviewed journal. That limits independent examination of subgroup outcomes, missing-data handling and the complete safety profile. The topline report is informative, but the full dataset will be essential for clinical and regulatory interpretation.
Retatrutide remains an investigational molecule and is not FDA-approved. The results do not create a new consumer treatment option today. They establish a stronger evidence base for a future decision about whether retatrutide’s efficacy, safety and tolerability justify approval and clinical use.
The week-80 numbers are impressive. The comparator, statistical design, discontinuation rates and approval status are just as much a part of the story. Serious science demands that they travel together.
Sources: Eli Lilly, October 28, 2026, TRANSCEND-T2D-2 topline announcement; ClinicalTrials.gov, NCT06260722.
